Telaleaf and Little Green Pharma Sponsor First Cannabis Certificate Course for Doctors in Germany
New York, NY, September 22, 2021 — TelaleafHealth Inc. (“Telaleaf” or the “Company”), a telemedicine companyrevolutionizing the delivery of cannabis care to patients, is pleased toannounce a joint sponsorship with a leading global medical cannabis company,Little Green Pharma Ltd. (or “LGP”), for the first certificate course fordoctors, pharmacists and relevant professionals interested in the prescriptionand treatment of cannabis-based products. The course is hosted by DresdenInternational University in Germany.
The course titled, “The A-Z of cannabis-based therapy: Basics andpractical use of cannabis-based drugs in medical practice and pharmacy” is acomprehensive, practice-oriented and interdisciplinary certificate course fordoctors, providing in-depth knowledge of all aspects of cannabis-based therapy,which doctors and pharmacists require for appropriate and responsibletherapeutic use of all cannabis-based drugs currently available forprescription. Upon completion of the course, advanced training points areawarded by the Saxon State Medical Association for those who have theappropriate professional affiliation.
The course curriculum is developed, led and instructed by threeleading scientific and clinical experts in cannabis medicine: Dr. FranjoGrotenhermen, Dr. Kristen Müller-Vahl and Dr. Dennis Stracke. The many years ofindividual and combined clinical, practical and scientific experience of theselecturers will be of immense value to the course participants, as well as theirexcellent knowledge of emerging cannabis laws and the current political and legallandscape in Germany, Europe and beyond.
Dr. Franjo Grotenhermen is a world-renown leader and expert on thetherapeutic use of cannabinoids. He is the chairman of the Cannabis Association(ACM), and founder and Managing Director of the International Association forCannabinoid Medicines (IACM) for over 20 years. His book, "CannabisHealing" is recognized as the most authoritative guide on the therapeuticapplication of medical cannabis. His expertise is highly respected andsought-after amongst governmental bodies, pharmaceutical companies andinternational institutions such as the World Health Organization and theAmerican Herbal Pharmacopoeia.
Dr. Kirsten Müller-Vahl is a specialist in both neurology andadult psychiatry. She is Professor and Managing Senior Physician at the Clinicfor Psychiatry, Social Psychiatry and Psychotherapy at the Hannover MedicalSchool. Her scientific work includes the role of the endocannabinoid system inpsychiatric disorders and treatment studies using cannabinoid modulators andcannabis-based medicines. She has led several clinical trials investigating theefficacy of cannabis-derived drugs. She is routinely invited as an expert tothe German Bundestag for hearings on the new German cannabis law.
Dr. Dennis Stracke is Head of Pharmacy Neurology and RareDiseases, Medios Apotheke Anike Oleski in Berlin as well as board member of theAssociation of Cannabis Supplying Pharmacies (VCA) and on the ScientificAdvisory Board at the Federal Association of Pharmaceutical CannabinoidCompanies (BPC).
Gavin Treanor, CEO of Telaleaf, stated: “This certification comesat a time of critical need for all levels of cannabis-based education todoctors. It is with the goal of meeting this need, by delivering top qualityeducation, that Telaleaf has aligned with Little Green Pharma, in a jointmission to facilitate doctor and practitioner access to expert-level trainingfrom the world’s most respected pioneers and leaders in cannabis-based medicinetoday.”
“As the cannabis space continues to evolve, there will be anongoing need for education, training and pedagogy to doctors and practitionersthat is not only engaging and flexible but highly sophisticated. The blendedlearning approach of our course combines self-study, and intensive face-to-faceand online group work, to incubate ideal conditions for skill acquisition andapplication. Telaleaf believes adequate doctor education enhances patienttreatment and experience. Success in cannabis medicine starts with pedagogicalmodels that close the gap between theoretical and practical application toraise the clinical standard among doctors for the appropriate therapeutic useof cannabis-based products.”
LGP Chief Operations Officer, Paul Long said: “At LGP we are firmbelievers that quality education is one of the key drivers to building theglobal medicinal cannabis industry, so we are delighted to be sponsoring such acomprehensive, practical, and credible course with Telaleaf. Our experience isthat educated doctors frequently become strong advocates for medicinal cannabistherapy, and we believe this education will help give German healthcareprofessionals the confidence to prescribe medicinal cannabis for theirpatients.”
The first certificate course kicks off September 30, 2021 and isnow full. To register for the next course, go to: telaleaf.com/doctors.
Telaleaf is a telemedicine company revolutionizing the delivery ofcannabis care by connecting patients to expert doctors, trained incannabis-based medicine, who conduct virtual medical visits. Our aim is toimprove patient outcomes by improving the patient experience with cutting-edgetechnology, simplicity, low costs and expert-led education to doctors andpractitioners, for the most advanced virtual care in cannabis medicine.
About Little Green Pharma
Little Green Pharma is a leading global medicinal cannabisbusiness with key production assets in Australia and Europe. Our goal is toimprove patient access to GMP-grade cannabis medicines around the world andtransform lives for the better. To achieve this, we prioritize assistingdoctors with ongoing education on treatment benefits and with the prescribingprocess to make it as simple as possible.